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Abstract 
Objectives 
The Norwegian Government urges that actions are needed to stimulate the working 
capacity in disability pension (DP) recipients with such a potential. Identification of 
factors that may impair rehabilitation efforts, such as information on the start of 
benzodiazepines in DP recipients, may be useful information in this context. 
Thus, the aim of the study was to describe the association between receipt of disability 
pension and later prescriptions of benzodiazepines among non-users at baseline. 
Methods  
We followed a cohort reporting non-use of benzodiazepines, 6645 men and 6455 
women aged 40-42 years who underwent health surveys in 1985 to 1989 in two 
Norwegian counties, with respect to subsequent use of benzodiazepines by linkage to 
the Norwegian Prescription Database for 2004-2006. At baseline, 83 men and 163 
women reported to receive DP. 
Results  
In both gender, the proportion started on at least one prescription of a benzodiazepine 
was about doubled among those reporting to be on a DP  20 years in the past,  21 % of 
all men and 29 % of all women, respectively. 
Univariate odds ratio for a benzodiazepine prescription for men and women on a DP 
were 2.6 (95% CI 1.5- 4.4) and 2.1 (1.5-2.9), respectively, as compared with those not 
receiving a DP. After adjustment for alcohol, smoking habits, physical activity,  socio-
economic and health  variables, the odds ratios was lowered for both sexes, being  2.1 
(1.2-3.7) (men) and 1.6 (1.1-2.3) (women).  
Conclusions  
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For both men and women the chance of being prescribed benzodiazepines was higher 
among those reporting to DP recipients 20 years in the past. 
 
 
 
Key words: employment status, disability pension, benzodiazepines, longitudinal 
studies, pharmacoepidemiology, prescription database, Norway 
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Background 
Despite above average life expectancy, Norway has a higher share of people on disability 
benefits, than most other OECD countries [1]. As a result, 11 per cent of the working 
population (18-67 years) received a disability benefit in Norway in 2006 [2]. In Norway, 
an insured (National Insurance Scheme) person between 18-67 years, whose working 
capacity is permanently reduced by 50 per cent due to illness, injury or defect is entitled 
to a disability benefit. Today, two different disability benefit schemes exist in Norway: 
time limited disability benefit and disability pension. Traditionally a disability pension 
was granted on a permanent basis. However, during the last decade The Norwegian 
Government have introduced several policy changes to arrest the upward trend; the time 
limited disability benefit including follow-up by The Norwegian Labour and Welfare 
Service (NAV) was introduced to prevent claims of permanent disability pensions. In 
addition, initiatives aiming at the reintegration into the labour market of those already on 
a disability pension have been launched.  The Norwegian Government urges, however, 
that further actions are needed to stimulate the working capacity in disability pensioners 
with such a potential.  
 
Several cross-sectional studies have shown that non-participation in the labour market 
seems to be associated with more frequent use of anxiolytics, hypnotics and/or 
benzodiazepines [3-7]. This association is, however, difficult to interpret in cross-
sectional studies. The higher use among those not employed may, on one hand, be 
explained by drug use as a proxy of mental illness, the precipitating reason for disability 
in the first place. On the other hand, and irrespective of the precipitating cause of 
disability, it is reasonable to believe that being on a disability pension may be associated 
with a number of psychological problems caused by, for instance, social isolation. Thus, 
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drug treatment with anxiolytics, hypnotics and benzodiazepines may be initiated to 
relieve these symptoms.  
 
It is well accepted that, even at therapeutic doses, benzodiazepines are capable of causing 
physiological and pharmacological dependence leading to withdrawal syndrome after 
cessation of use [8]. In addition, benzodiazepines impair psychomotor skills and 
cognitive functions, interfering with people’s daily functioning [9] .Thus, initiation of 
benzodiazepines among disability benefit recipients might lead to a further impairment of  
health and rehabilitation efforts, contributing to a consolidation of the disability situation. 
Interestingly, randomised controlled trials have shown that withdrawal from 
benzodiazepines give significant better psychomotoric function compared to the control 
group remaining on benzodiazepines [10, 11].  
The Norwegian Government urges that large efforts will be needed to bring those of the 
disability pensioners who are able to work into employment.  Identification of factors that 
may impair rehabilitation efforts, such as information on the initiation of  
benzodiazepines in DP recipients, may be useful information in this context.  
Aims 
To our knowledge, the epidemiology of incident drug-taking behaviours in general, and 
use of benzodiazepines in particular, among disability pensioners are scarcely described 
in the literature. A longitudinal design, with data from the Norwegian health surveys in 
1985-1989 linked to data from a prescription database in 2004-2006, was used to 
investigate the association between the receipt of disability pension among 40-42 year old 
non-users of benzodiazepines and prescriptions of benzodiazepines 20 years later, a span 
covering a larger part of the potential active workforce period. 
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Material and methods 
Health surveys-information on independent variables 
All men (15 606) and women (14 748) aged 40-42 in the two Norwegian counties of 
Østfold and Aust-Agder were invited to participate in a population-based health survey 
organised by the National Health Screening Service, and has been described earlier [12-
14] . The health survey was directed toward cardiovascular disease. Two examinations 
targeting two different generations of 40-42 years at the time of survey were carried out 
with three years interval both in Østfold (1985 and 1988) and in Aust-Agder (1986 and 
1989). The total response rate was high; 72 % for men and 81 % for women.  
The participants completed a self-administrated questionnaire covering different 
sociodemographic-, health- and lifestyle variables such as disability status, smoking, 
physical activity and others. A physical examination comprised measurements of weight, 
height, blood pressure. At the examination site an additional questionnaire was handed 
out to be filled out at home and returned by mail. All participants who where medically 
examined received this questionnaire. The response rate was 82 %. The questionnaire 
included separate questions covering alcohol use, use of analgesics, anxiolytics or 
hypnotics. In addition, in the surveys in 1988 and 1989 (and therefore a sub-sample of 
our study population), the second questionnaire included a question regarding nervous or 
mental health problems as told by the doctor. Details from the questionnaire, from which 
the variables are defined, are described in Table 1. 
 
We excluded from our study persons who died or emigrated from Norway (451 men and 
326 women) before January 2004 (Figure 1). In a second step we removed all those who 
received drugs reimbursed due to cancer diseases defined as the code §9.9 in the 
reimbursement scheme (93 men and 80 women).  
Further, to study incident use of benzodiazepines we excluded current users at baseline. 
The participants answered whether they used anxiolytics or hypnotics in one question 
which did not distinguish between these two drug classes (Table 1). Benzodiazepines 
represented 99 % of all sale anxiolytics/hypnotics in 1980ies in Norway and therefore 
anxiolytic/hypnotic users will be referred to as benzodiazepine users [15]. A majority of 
6645 men and 6455 women were defined as nonuser of benzodiazepines at baseline in 
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1985-89 according to this definition, and these persons were followed up with respect to 
subsequent prescription of benzodiazepines in 2004-2006. Parallel, among the 
participants who had received a questionnaire including a question regarding mental 
health symptoms, 3660 men and 3261 women were followed up with respect to 
subsequent prescription of benzodiazepines in 2004-2006. 
 
In addition to disability status, several other factors associated with the use of 
benzodiazepines were included in our analysis; age, gender, alcohol consumption and 
smoking habits, marital status, physical activity, use of analgesics,  somatic 
(cardiovascular morbidity) and nervous/mental health problems. See Table 1 for details 
on questions and variable definition. Analgesics users were defined as persons who 
answered they had used analgesics daily or every week during the last month (Table 1). 
Persons who used analgesics less than every week were defined as non-users according to 
probable common monthly use of analgesics among women due to menstrual pain. 
Analgesics use was defined in the same way for men.  
 
Norwegian Prescription Database (NorPD) - information on dependent variables 
Prescription data about benzodiazepines in 2004-2006 were drawn from the NorPD 
which covers the entire nation (4.6 million inhabitants) [16]. From 1 January 2004 all the 
pharmacies in Norway became legally obliged to send in all electronic data on 
prescriptions. These returns are sent to the Norwegian Institute of Public Health. NorPD 
contains information of all individuals who have received prescription drugs dispensed at 
pharmacies. All prescriptions reimbursed or not, are stored in the database. The drugs are 
classified according to the Anatomical Therapeutic Chemical (ATC) classification system 
[17]. The data collected for our study were patients unique identifying number 
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(encrypted), sex, age, the date of dispensing, and drug information (brand name, package 
size, number of packages, ATC-code, Defined Daily Dose (DDDs), price). The code of 
reimbursement is also recorded and this may function as a proxy of diagnosis. Code §9.9 
is dedicated to cancer diseases.  
 
The benzodiazepines were defined by the ATC-code N05BA and N05CD in the ATC-
classification system. Use of benzodiazepines was defined as at least 1 prescription of a 
benzodiazepine during study period 1 January 2004 - 31 December 2006.  
In addition, and among benzodiazepine users, the amount of benzodiazepines during the 
same period in terms of total DDDs was analysed.  
 
Data from the health surveys and NorPD were linked based on the unique 11-digit 
identification number, assigned to all individuals living in Norway.  
 
Statistics  
Chi-square test was used to assess equality of proportions across the groups of drug use. 
Fishers exact test were used when the expected count in cells were less than 5.Mann-
Whitney test was used for variables with a skewed distribution.  Odds ratio (OR) with 95 
% confidence intervals (CI) were estimated separately for men and women by logistic 
regression. All analyses were done using SPSS 16.0 for Windows. Level of significance 
was set to p<0.05.  
 
Ethical considerations 
The study protocol was assessed by the Regional Committee for Medical Research Ethics 
and approved by the Norwegian Data Inspectorate. The study has been conducted in full 
accordance with the World Medical Association Declaration of Helsinki.  
Results 
Characteristics of the study population, non-users of benzodiazepines at baseline, are 
shown in table 2. The proportion of 40-42 year old individuals reporting to be receivers 
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of  a disability pension was about doubled in women (N=163; 2.5%) as compared to  men 
(N=83; 1.3 %) (Table 2). There was a higher prevalence of teetotallers, current daily 
smokers (women only), and physically inactive persons among receivers of a disability 
pension. There was also a higher prevalence of unmarried, cardiovascular history, and use 
of analgesic drugs among those reporting to be on a disability pension. 
 
In both gender, the proportion who received at least one prescription of a benzodiazepine 
20 years later was about doubled among those reporting to be on a disability pension 
when aged 40-42 in 1985-89, 21 % of all men and 29 % of all women, respectively (table 
2). Further, median DDD of benzodiazepines retrieved among users during the study 
period were increased, but not significantly, among receivers of a disability pension in 
both gender, 50 versus 30 DDD respectively (table 2).  
 
Univariate OR for incident use of benzodiazepines among disability pensioners were 2.6 
(1.5-4.4) in men and 2.1 (1.5-2.9) in women, respectively, as compared with those 
reporting to be non-receivers of a disability pension 20 years in the past (table 3). After 
adjustment for lifestyle, health, and socio-economic variables the OR was lowered for 
both sexes, being 2.1 (1.2-3.7) (men) and 1.6 (1.1-2.3) (women).  
 
Adjustment for nervous or mental health problems as told by the doctor was possible only 
in a sub-sample of the study-population who had answered this question. 
In gender specific analyses, adjustment for mental health problems at baseline gave a 
higher OR for benzodiazepines 20 years later in male disability pensioners (2.6 (1.3-5.5)). 
The same trend was observed among women, however the OR for later benzodiazepines 
became non-significant (OR 1.4 (0.8-2.2)).  Overall, adding adjustment for mental health 
problems and gender into the multivariate analysis, revealed an OR for benzodiazepines 
among receivers of a disability pension of 1.6 (1.1-2.5). 
 
Discussion 
The proportion that had started benzodiazepines, were doubled in those reporting to be 
disability pensioners at the age of 40-42, compared to those reporting not to be on a 
disability pension at baseline.  
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Our results may to some extent reflect what is generally well known; that BZD use 
increases with age. However, our design, comparing incident BZD use in DP recipients 
with the remaining population, highlight that excessive incident BZD use may be 
attributed to the DP situation. This observation was supported by our multivariate 
analysis where the receipt of a disability pension had an independent effect on incident 
use of benzodiazepines 20 years later, after controlling for alcohol, smoking habits and 
several other potential confounders. In Norway, and other OECD countries, mental health 
disorders and musculoskeletal problems are the main reasons for disability benefit claims 
[2]. Further, cross-sectional studies have disclosed that mental health factors, anxiety 
disorders in particular, predicts benzodiazepine use [7]. A higher incidence of 
benzodiazepine use among those reporting to be on a disability pension may be explained 
by a higher prevalence of mental health symptoms in this group at baseline. However, 
adjusting for nervous/mental health problems, as told by the doctor, in a sub-group of our 
study population, still revealed an independent effect of self-reported disability pension 
on use of benzodiazepines 20 years later, most pronounced in men. Obviously limitations 
in using this variable to adjust for mental illness at baseline exist, and the results should 
be interpreted with caution. A discrepancy between the actual mental symptom load and 
the individuals response to this question may be caused by several factors such as; the 
respondents recall, the subjective interpretation of the physician `s message, as well as 
interpretation of the question in the questionnaire.  
 
 
It is a general observation that there exist two female BZD users for every male user of 
BZDs, as reflected in prescription data among 60-69 year old as well as in the total 
Norwegian population [18]. Obviously, more women are started on BZDs, as reflected in 
our results as well. The non-significant interaction supports the view that the risk ratio (or 
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odds ratio) between women and men in being prescribed a BZD is the same in people 
receiving and people not receiving a disability pension.  
 
  
A limitation of our study is the description of use of benzodiazepines according to self-
reported disability status 20 years in the past. The proportion on a disability pension 
increases with age; e.g. in 2006 about 25% of all men and 37 % of all women aged 60 
years  in Norway were receivers of a disability pension, as compared to 1-2% of the 40-
42 year old participants in our study [2]. Thus, an unknown number of the initially non-
disabled 40-42 years old will have changed their disability status during this period. In 
this situation, the OR estimates as presented will be underestimated, and biased towards 
the null.   
Another limitation is that no information is available on use prior to the period covered 
by the questionnaire or in the 20 year lasting period between the two measurement points. 
It may very well be that some of the current users also used benzodiazepines regularly or 
in periods preceding the presentation of the questionnaire. Further, in this study 
benzodiazepine use is defined according to the retrieval of one prescription of a 
benzodiazepine during a three years period. In Norwegian recommendations 
benzodiazepines are recommended for short-term use only, up to 2-4 weeks, in treatment 
of severe anxiety and insomnia [19].  One prescription of a benzodiazepine is neither an 
outcome for long-term use, nor an addictive use pattern, and should be interpreted with 
caution.  
 
In the present study we chose to focus on later prescriptions of traditional 
benzodiazepines, with its well known potential of causing addiction problems and other 
negative effects interfering with people’s daily functioning [8, 9]. Thus, we excluded 
prescriptions on benzodiazepine-like hypnotics from our analysis. In Norway 
benzodiazepine-like hypnotics are now recommended as first-choice hypnotics for short-
term use in severe insomnia. These substances, zopiclone in particular, are the most 
commonly used hypnotics in Norway. Hence, about 90 %  of all 60-69 years olds who 
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retrieved at least one prescription on a hypnotic in Østfold an Aust-Agder in 2006  were 
users of benzodiazepine-like hypnotics [18]. Recent literature, however, adds to the 
growing evidence that these substances have a similar potential for negative effects as 
traditional benzodiazepines [20-22]. Still we wanted to restrict our analysis to the 
prescription of the traditional benzodiazepines, which constitute a better documented 
marker of an addictive use pattern [14, 20, 23]. 
 
This study is prospective with a nationwide register as an end-point, which implies 
minimal risk of selection or information bias. Another strength of our study is the narrow 
age range, since age as an important confounder is taken into account in the design. 
However, we cannot assess whether these findings are valid for other age-groups. 
Further, even if many potential confounders associated with prescription of 
benzodiazepines are registered, not all possible confounders could be taken into account.  
For example, we do not know the indication for later prescriptions of benzodiazepines. 
No evaluation of the non-attendees was performed in this study. However, receivers of 
disability pension were over-represented among the non-attendees in a parallel 
Norwegian health survey [24]. Lower attendance of disability pensioners, presumably 
with poorest health, will most likely have biased our OR estimates towards null.   
 
 
In conclusion, this prospective study provides evidence of an increased risk of the 
initiation of benzodiazepines among those reporting to be disability pensioners 20 years 
in the past. The limitations with our study-design do not allow us to conclude neither on 
long-term use or an addictive use pattern,  in which there is a particular concern regarding 
the negative effects of benzodiazepines interfering with people’s daily functioning [9]. 
However; about 20% of all men and 30% of all women reporting to be disability 
pensioners at the age of 40, had started benzodiazepines 20 years later, a period covering 
most of their potential workforce period.  
Being on a disability pension may be a positive alternative to join the workforce. 
However, many disability pensioners  perceive their disability situation as passive, 
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unwanted and experience themselves as being  excluded  from the strong social and  
personal values associated with being a part of the workforce [25]. Reintegration into the 
labour market of disability pensioners with a working capacity has been an important part 
of the political agenda in Norway the last decade. Our findings may highlight the need of 
further research in this area. More detailed information on the use pattern of 
benzodiazepines among disability pensioners are needed to make conclusions on 
”problematic” use, with a potential to add up as yet another factor contributing to a 
consolidation of the disability situation. 
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Figure 1. Flow chart for the study population. Health surveys in Østfold and Aust-
Agder   (1985-89) 
Responders, men
n=7605
Died or emigrated 
before 2004
n=451
7154
7061
6645 (3660*)
Users of 
benzodiazepines
at baseline
n=416
Cancer diseases
n=93
Responders, women
n=8062
Died or emigrated 
before 2004
n=324
7736
7656
6455 (3261*)
Users of 
benzodiazepines 
at baseline
n=1201
Cancer diseases
n=80
 
 
 
*participants in 1988-89; sub-sample of the study-population who had received and 
answered a questionnaire including a question regarding nervous or mental health 
problems as told by their doctor. 
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Table 1.  Questions and variable definition on drug use and other factors with answering alternatives used in the health survey in Østfold (1985 
and 1988) and Aust Agder (1986 and 1989). 
Self-administered questionnaire Answering alternatives Variable definition 
Anxiolytics/hypnotics*    
How often have you used anxiolytics or hypnotics 
during last month?* 
Daily (1); every week, but not daily (2); less than every 
week (3); not used during last month (4) Users = 1-3; non-users = 4 
Analgesics   
How often have you used analgesics during last 
month? 
Daily (1); every week, but not daily (2); less than every 
week (3); not used during last month (4) Users = 1,2; non-users = 3,4 
Alcohol consumption habits    
How often have you drunk beer, wine or spirits 
during the last 14 days? 
Teetotaller (1); not during the last 14 days, but are not a 
teetotaller (2); 1-4 times (3); 5-10 times (4); > 10 times 
(5) 
Teetotaller =1; normal drinker =2,3; problem 
drinker=4,5 
Smoking habits      
Do you smoke daily at present? Yes (1)/no (2) Smokers =1; ex-smokers= 3; non-smokers =2,4 
Did you smoke earlier? Yes (3)/no (4)  
Physical activity   
Describe the physical activity in your spare-time, 
on average during the last year. 
Description of four levels of physical activity, sedentary 
to intense, in spare time.(1-4) seldom/never physical active  =1; active =2-4 
Cardiovascular symptomes   
Previous MI, angina, stroke, diabetes Yes (1)/no (2) CVD history =1 or 3 ; no CVD history = 2 and 4 
Descriptions of symptoms  Yes (3)/no (4)  
Working status   
Do you receive full or reduced disability pension?  Yes (1)/no (2) Receivers of a disability pension=1; non-receivers =2 
Mental health problems**   
Have you ever been told by your doctor that you 
have nervous or mental health problems? Yes (1)/no (2) nervous/mental health problems=1; non-presence=2 
* 99% of anxiolytics/hypnotics sale in Norway in 1989 ies were benzodiazepines.                
 **Only included in the  questionnaires in health surveys in 1988 and 1989  
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Table 2.  Baseline characteristics for men and women aged 40-42 years which were nonusers of  benzodiazepines when surveyed in 1985-1989. 
Use of  benzodiazepines retrieved from the Norwegian Prescription Database in  2004-2006. 
  Men   Women 
  
Disability pension             
(1985-1989)     
Disability pension              
(1985-1989)   
 Yes (N=83) No (N=6553) p  Yes (N=163) No (N=6284) p 
Baseline characteristics 1985-1989        
Alcohol habits         
     Teetotallers 17 (21.5) 579 (8.9)   42 (26.1) 1102 (17.6)  
     Normal consumption 57 (72.2) 5273 (80.8)   114 (70.8) 4891 (78.3)  
     High consumption  5 (6.3) 673 (10.3) ***  5 (3.1) 256 (4.1) * 
Smoking habits        
     Current daily smokers  42 (50.6) 2608 (39.8)   74 (45.4) 2176 (34.6)  
     Ex-smokers  23 (27.7) 2124 (32.4)   49 (30.9) 2120 (33.7)  
     Non smokers 18 (21.7) 1821 (27.8) 0.132  40 (24.5) 1988 (31.6) * 
Seldom/never physical active 28 (34.1) 1269 (19.4) ***  60 (36.8) 1350 (21.5) *** 
Married  51 (61.4) 5732 (87.6) ***  108 (66.3) 5462 (87.0) *** 
Cardiovascular history 10 (12.0) 340 (5.2) **  20 (12.3) 290 (4.6) *** 
Analgetics use 15 (18.1) 225 (3.4) ***  48 (29.4) 500 (8.0) *** 
        
Prescription of BZDs in 2004-2006
 a
         
     Use of benzodiazepines (%)
 
 17 (20.5) 602 (9.2) ***  48 (29.4) 1059 (16.4) *** 
        Median DDD (IQR) among users  50 (25,160) 30 (13,120) 0.189  52 (13,265) 30 (10,100) 0.059 
        % > 100 DDD among users
 
 5 (29.4) 159 (26.4) 0.781   15 (31.3) 244 (23.0) 0.189 
*p-value<0.05; **p-value<0.01; ***p-value<0.001      
a
 use/users of BZDs was defined as the retrieval of at least 1 prescription of a BZD (N05BA/N05CD) during study period 2004 - 2006 
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Table 3. Association between receipt of disability pension in 1985-1989 with incident prescription of benzodiazepines in 2004-2006. Unadjusted 
and adjusted odds ratio (OR) with 95% confidence intervals. 
 Men  Women 
  
Prescription of 
benzodiazepines  
in 2004-2006   
Prescription of benzodiazepines                   
in 2004-2006 
  
Unadjusted  
OR (95% CI) 
Multivariate* 
OR (95% CI)  
Unadjusted   
OR (95% CI) 
Multivariate* 
OR (95% CI) 
Disability pension in 1985-1989      
No - reference 1.0 1.0  1.0 1.0 
Yes 2.6 (1.5-4.4) 2.1 (1.2-3.7)  2.1 (1.5-2.9) 1.6 (1.1-2.3) 
          
*adjusted for alcohol habits, smoking habits, physical activity,  marital status,  cardiovascular symptoms and use of analgesics 
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